ArticleCureus2025
Improving Helicobacter pylori Treatment Standards: A Quality Improvement Project Against Maastricht VI Guidelines.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact ofJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori is a common infection associated with dyspeptic symptoms and long-term gastrointestinal complications when left untreated. This quality improvement project (QIP) was conducted over a six-month period with the aim of evaluating current diagnostic practice, treatment regimens, follow-up completion, and eradication outcomes in patients managed for H. pylori infection. A total of 200 adult patients were included, with a median age of 39 years and a slightly higher representation of men. Epigastric pain and burning were the most frequently reported symptoms, followed by nausea and bloating. Diagnosis was confirmed in all patients using the urea breath test or endoscopy-based methods, demonstrating appropriate compliance with recommended diagnostic standards. Bismuth-based quadruple therapy was the most commonly prescribed regimen, while clarithromycin-based triple therapy was used in a smaller proportion of cases. Follow-up attendance was recorded in 125 patients, and 90 of these underwent re-testing one month post-therapy. Successful eradication was documented in 72 of the retested patients, reflecting an 80% eradication rate in those who returned for confirmation. Among the 90 patients who underwent re-testing after follow-up, 80% (72/90) achieved successful eradication. Although the cure rate among retested patients was satisfactory, overall eradication confirmation represented only 36% of the total treated population due to incomplete follow-up and low re-testing rates. Strengthening patient education regarding the importance of treatment adherence, test-of-cure verification, and timely review may improve future outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.